The short answer is that PRP injections for knee osteoarthritis probably work, but the degree to which they work depends heavily on the specific preparation used, how many injections you get, and how severe your arthritis is. A 2025 meta-analysis published in the American Journal of Sports Medicine, drawing from 28 randomized controlled trials and 3,246 patients, found that PRP provides clinically significant functional improvement at one, three, six, and twelve months, along with meaningful pain relief at three and six months compared to placebo. That is a genuinely encouraging finding. But it comes with important caveats that most clinic marketing materials conveniently leave out.
The picture gets more complicated when you look at the full body of evidence. The landmark RESTORE trial, published in JAMA in 2021, found that PRP did not significantly improve knee pain or cartilage volume compared to saline placebo at twelve months. That single study remains one of the most rigorous placebo-controlled trials ever conducted on PRP for knee osteoarthritis, and its results directly contradict the more optimistic meta-analyses. How do you reconcile these findings? The emerging consensus is that not all PRP is created equal, and that preparation details — platelet concentration, leukocyte content, number of injections — matter enormously. This article walks through what the latest research from 2025 and 2026 actually shows about PRP for knee pain, including the optimal protocols that appear to produce the best results, how PRP stacks up against hyaluronic acid, what it costs out of pocket, who is most likely to benefit, and where the evidence still falls short.
Table of Contents
- What Does the Latest PRP Research Actually Show About Knee Pain Relief?
- PRP vs. Hyaluronic Acid — Which Injection Works Better for Knee Osteoarthritis?
- Who Benefits Most from PRP Knee Injections?
- How Much Do PRP Injections Cost, and Will Insurance Cover Them?
- The Limitations and Unknowns That Still Surround PRP Therapy
- Safety Profile of PRP Injections for Knee Osteoarthritis
- What Ongoing Trials Will Tell Us Next About PRP for Knee Pain
- Conclusion
- Frequently Asked Questions
What Does the Latest PRP Research Actually Show About Knee Pain Relief?
The most important development in PRP research over the past two years has been the shift from asking “does PRP work?” to asking “which PRP works, and how should it be delivered?” A 2025 meta-analysis published in Frontiers in Physiology found that repeated PRP injections were roughly four times more effective than a single injection in reducing pain, with the most commonly studied and successful protocol being three weekly injections. Meanwhile, a 2026 meta-analysis published in PM&R confirmed that outcomes are directly associated with total deliverable platelet count — in plain terms, higher platelet doses produce better results. The optimal platelet concentration appears to fall in the range of 600 to 900 × 10⁹ per liter, with three to five injections at seven- to fourteen-day intervals yielding the best outcomes, according to the 2025 American Journal of Sports Medicine analysis. High-platelet PRP provided superior and more durable results than low-platelet PRP.
This matters because many clinics use simple tabletop centrifuge kits that may not consistently produce platelet concentrations in this range. A patient receiving a single injection of low-concentration PRP from one clinic could have a completely different experience than someone receiving three injections of high-concentration PRP from another, and both would technically be receiving “PRP therapy.” There is also growing evidence that leukocyte content matters. A 2025 review in the Journal of Clinical Medicine found that leukocyte-poor PRP demonstrates superior pain relief and functional improvement compared to leukocyte-rich PRP, particularly in patients with mild-to-moderate osteoarthritis classified as Kellgren-Lawrence grades I through III. The white blood cells in leukocyte-rich preparations may trigger inflammatory responses that counteract some of the regenerative benefits, though this remains an active area of investigation.
PRP vs. Hyaluronic Acid — Which Injection Works Better for Knee Osteoarthritis?
For years, hyaluronic acid injections were the go-to non-surgical injection option for knee osteoarthritis, covered by many insurance plans and widely available. PRP has increasingly been positioned as the superior alternative, and the latest evidence largely supports that claim. A 2025 meta-analysis of 42 randomized controlled trials, published in Frontiers in Surgery, found that PRP significantly outperformed hyaluronic acid on WOMAC total score and physical function at both six and twelve months. At twelve months, PRP patients had significantly lower WOMAC pain scores, with the difference exceeding the minimal clinically important difference — meaning the improvement was not just statistically significant but large enough for patients to actually notice. This finding was significant enough to influence professional guidelines.
The European Society for Sports Traumatology, Knee Surgery, and Arthroscopy now explicitly recommends PRP over hyaluronic acid for knee osteoarthritis treatment, issuing this as a level B recommendation. That represents a meaningful shift in the clinical establishment’s stance on a therapy that was long considered experimental. However, this comparison comes with a critical practical caveat: hyaluronic acid injections are typically covered by insurance, while PRP is not. A patient choosing PRP over hyaluronic acid may get better results, but they will pay anywhere from $1,500 to $6,000 out of pocket for a three-injection series versus a modest copay for hyaluronic acid. For patients on fixed incomes or with limited savings — a demographic that overlaps heavily with older adults managing knee osteoarthritis — the superior efficacy of PRP may be irrelevant if they simply cannot afford it. And for patients with advanced osteoarthritis beyond Kellgren-Lawrence grade III, the evidence for PRP superiority becomes much less clear.
Who Benefits Most from PRP Knee Injections?
The research increasingly points toward a specific patient profile that is most likely to benefit from PRP: someone with mild-to-moderate knee osteoarthritis, classified as Kellgren-Lawrence grades I through III, who receives leukocyte-poor PRP at an adequate platelet concentration across multiple injection sessions. A 65-year-old with early cartilage thinning and intermittent knee pain during walks, for example, is a much better candidate than a 78-year-old with bone-on-bone arthritis who can barely climb stairs. This distinction matters enormously and is something that aggressive clinic marketing often obscures. The studies showing the strongest PRP benefits have generally enrolled patients with earlier-stage disease. The RESTORE trial, which found no significant benefit over placebo, included patients across a wider range of disease severity and used a single injection protocol.
While some have argued that the RESTORE trial’s PRP preparation may not have been optimized, it remains a sobering reminder that PRP is not a universal solution for all knee pain. For older adults and their families — particularly those already navigating complex health decisions related to cognitive decline or dementia — it is worth noting that knee pain and mobility limitations are closely linked to overall health outcomes. Reduced mobility is a well-established risk factor for cognitive decline, depression, and loss of independence. An effective treatment for knee pain that helps maintain walking ability and physical activity could have downstream benefits that extend well beyond the joint itself. But the treatment needs to actually work for the specific patient, and right now the strongest evidence favors earlier intervention in milder disease.
How Much Do PRP Injections Cost, and Will Insurance Cover Them?
PRP injections cost between $500 and $2,000 per injection depending on provider and region, with average costs running approximately $728 to $1,200 per session. Given that the optimal protocol appears to involve three to five injections, a full course of treatment could cost anywhere from $2,200 to $6,000 out of pocket. This is not a trivial expense, especially for a treatment that may need to be repeated annually or biannually to maintain benefits. Insurance coverage is essentially nonexistent. Medicare, Blue Cross Blue Shield, Cigna, Aetna, and UnitedHealthcare all classify PRP as experimental and generally do not cover it.
TRICARE, which had previously offered limited coverage, ended that benefit in September 2024. This means the financial burden falls entirely on the patient, and it creates a stark equity issue: a treatment that appears to work reasonably well is available primarily to those who can pay cash for it. A Cleveland Clinic cost-effectiveness analysis offered a nuanced perspective. PRP may be more cost-effective for patients with higher surgical risk or significant comorbidities, where knee replacement surgery carries greater costs and complication rates. For an 80-year-old with dementia who is not a good candidate for general anesthesia and total knee replacement, a series of PRP injections that provides six to twelve months of improved mobility could be a genuinely practical alternative — even at $3,000 out of pocket — compared to the risks and recovery demands of major surgery. For average patients without elevated surgical risk, the primary barrier to cost-effectiveness is efficacy duration rather than injection cost.
The Limitations and Unknowns That Still Surround PRP Therapy
The single largest problem in PRP research is heterogeneity. The term “PRP” encompasses a wide range of preparations that differ in platelet concentration, leukocyte content, activation protocols, volume injected, and injection frequency. Comparing PRP studies is a bit like comparing “medication” studies without specifying the drug, dose, or schedule. Multiple systematic reviews from 2025 and 2026 have flagged this as the central challenge in drawing definitive conclusions about PRP efficacy. This heterogeneity means that when your orthopedic surgeon or sports medicine doctor says “the evidence supports PRP,” they may be technically correct about the aggregate data while telling you very little about what you will actually receive in their office. The PRP preparation from a high-volume sports medicine clinic using a specialized double-spin centrifuge system may produce a fundamentally different product than what comes from a tabletop kit in a general practice office.
There are no standardized regulations requiring clinics to disclose their platelet concentration, leukocyte content, or preparation method to patients. You should ask, but many providers may not routinely test or report these values. The RESTORE trial also raises a question that the field has not fully resolved. If PRP is genuinely effective, why did a well-designed, adequately powered, placebo-controlled trial find no benefit? Proponents argue that the trial used a single injection of a specific PRP formulation that may not have been optimal. Critics argue that the positive meta-analyses are inflated by studies with weaker blinding, smaller sample sizes, and potential bias. Both arguments have merit, and honest clinicians will acknowledge this uncertainty rather than dismissing the RESTORE trial as an outlier.
Safety Profile of PRP Injections for Knee Osteoarthritis
On the safety front, PRP performs well. A 2025 review in the Open Access Journal of Sports Medicine found that adverse events are predominantly mild, transient, and localized. The most common side effect is a temporary pain flare-up at the injection site, which typically resolves within a few days. Serious complications are infrequent.
This favorable safety profile is one of PRP’s genuine advantages over alternatives like corticosteroid injections, which carry risks of cartilage degradation with repeated use, and surgical intervention, which involves anesthesia risks, infection potential, and lengthy rehabilitation. For older adults, particularly those with cognitive impairment, the low-risk nature of PRP is especially relevant. A procedure that can be performed in an office visit without sedation, with minimal post-procedure restrictions, is far more practical than one requiring hospitalization. The main risk is financial — spending significant money on a treatment that may not provide meaningful relief for a particular patient’s stage of disease.
What Ongoing Trials Will Tell Us Next About PRP for Knee Pain
UCSF is currently conducting a randomized, double-blind, placebo-controlled clinical trial testing PRP injections in both younger and older adults with knee osteoarthritis, including a crossover phase that will allow patients who initially received placebo to later receive PRP. This trial design is important because it may help address some of the methodological criticisms leveled at earlier studies and provide more definitive answers about age-specific responses to PRP.
The broader trajectory of PRP research is moving toward standardization — defining exactly which formulations work, at what doses, for which patients, and on what schedule. If the field can establish clear preparation standards and identify reliable biomarkers for predicting treatment response, PRP could move from its current status as a promising-but-variable therapy to a well-defined treatment protocol with predictable outcomes. Until that happens, patients and their families should approach PRP with informed optimism: the evidence is genuinely encouraging, but the gap between what the best studies show and what any given clinic delivers remains wide.
Conclusion
The latest research paints a cautiously optimistic picture of PRP for knee osteoarthritis. The aggregate evidence from large meta-analyses in 2025 and 2026 suggests that properly prepared PRP — leukocyte-poor, at platelet concentrations of 600 to 900 × 10⁹ per liter, delivered across three to five injection sessions — can provide meaningful pain relief and functional improvement that outperforms both placebo and hyaluronic acid. Professional bodies like ESSKA have taken notice, formally recommending PRP over hyaluronic acid for knee osteoarthritis. But the practical reality is more complicated.
PRP remains uncovered by insurance, costs $500 to $2,000 per injection, and its effectiveness varies substantially based on preparation methods that are neither standardized nor typically disclosed to patients. The RESTORE trial’s null findings have not been fully explained away. For older adults managing knee pain alongside other health challenges, PRP may be worth considering — particularly for those who are poor candidates for surgery — but it should be pursued with clear-eyed awareness of both its promise and its current limitations. Ask your provider about platelet concentration, leukocyte content, and the specific protocol they use. If they cannot answer those questions, that itself is useful information.
Frequently Asked Questions
How long do PRP injection results typically last for knee osteoarthritis?
Based on the 2025 meta-analyses, PRP provides clinically significant functional improvement through twelve months, with the strongest pain relief demonstrated at three and six months. However, many patients require repeat treatment cycles. The evidence on durability beyond one year is limited, and some patients report benefits fading at the nine- to twelve-month mark.
Are PRP injections painful?
The injection itself involves standard needle insertion into the knee joint, comparable to a cortisone or hyaluronic acid injection. The most common side effect is a temporary pain flare-up at the injection site lasting a few days. Serious complications are infrequent, and no sedation is required.
Can PRP injections help if I have bone-on-bone arthritis?
The strongest evidence for PRP benefits comes from patients with mild-to-moderate osteoarthritis, classified as Kellgren-Lawrence grades I through III. For advanced bone-on-bone arthritis at grade IV, the evidence is much weaker, and patients with severe disease were generally underrepresented or excluded from the most positive studies.
Why does my insurance not cover PRP if the research supports it?
Medicare, Blue Cross Blue Shield, Cigna, Aetna, and UnitedHealthcare all classify PRP as experimental. The heterogeneity in PRP preparations and the conflicting results between positive meta-analyses and the negative RESTORE trial give insurers justification to maintain this classification. TRICARE, which had briefly covered PRP, discontinued coverage in September 2024. This classification may change as standardization improves and larger definitive trials report results.
How many PRP injections do I need?
The 2025 research indicates that repeated PRP injections are approximately four times more effective than a single injection. The most commonly successful protocol is three injections at weekly or biweekly intervals, with platelet concentrations in the 600 to 900 × 10⁹ per liter range. A single injection is unlikely to produce optimal results.
Should I choose PRP or hyaluronic acid injections for my knee?
A 2025 meta-analysis of 42 randomized controlled trials found PRP significantly outperformed hyaluronic acid at both six and twelve months, and ESSKA now formally recommends PRP over hyaluronic acid. However, hyaluronic acid is typically covered by insurance while PRP is not. For patients who cannot afford $1,500 to $6,000 out of pocket for a PRP series, hyaluronic acid remains a reasonable and more accessible alternative.
